Correction: Pharmacokinetic Characteristics of Long‑Acting Injectable Antipsychotics for Schizophrenia: An Overview

Correction: CNS Drugs (2021) 35:39–59 10.1007/s40263-020-00779-5

In Fig. 2 of this article, two drug labels in the y axis were mislabeled, with aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL) having swapped positions; the corrected Fig. 2 should have appeared as shown below.

Fig. 2.

Peak-to-trough plasma concentration ratios of oral and long-acting injectable antipsychotics at steady state [36, 118–121]. AL aripiprazole lauroxil, AM aripiprazole monohydrate, ER extended release, LAI long-acting injectable, PP1M paliperidone palmitate once monthly, PP3M paliperidone palmitate every 3 months, qxw every x weeks, RLAI-MS risperidone long-acting injection microspheres

The original article has been corrected.